

Pedro P LÃ³pez-Casas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2330554/publications.pdf>

Version: 2024-02-01

45
papers

2,186
citations

236925

25
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

4727
citing authors

#	ARTICLE	IF	CITATIONS
1	Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. <i>British Journal of Cancer</i> , 2013, 109, 926-933.	6.4	251
2	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	7.0	140
3	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. <i>Clinical Cancer Research</i> , 2015, 21, 4811-4818.	7.0	117
4	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. <i>Cancer Cell</i> , 2020, 37, 340-353.e6.	16.8	114
5	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. <i>Clinical Cancer Research</i> , 2017, 23, 6661-6672.	7.0	110
6	Afatinib restrains K-RAS-driven lung tumorigenesis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	99
7	c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. <i>Cancer Cell</i> , 2018, 33, 217-228.e4.	16.8	93
8	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
9	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. <i>Journal of Clinical Oncology</i> , 2012, 30, e45-e48.	1.6	79
10	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	77
11	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	7.0	67
12	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. <i>Genome Medicine</i> , 2018, 10, 41.	8.2	63
13	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	6.4	63
14	Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. <i>Oncotarget</i> , 2017, 8, 35289-35300.	1.8	51
15	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
16	The expression patterns of genes involved in the RNAi pathways are tissue-dependent and differ in the germ and somatic cells of mouse testis. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2008, 1779, 306-311.	1.9	49
17	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 680-688.	4.1	49
18	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. <i>Clinical Cancer Research</i> , 2020, 26, 3420-3430.	7.0	47

#	ARTICLE	IF	CITATIONS
19	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	2.8	42
20	Transcriptional dissection of pancreatic tumors engrafted in mice. <i>Genome Medicine</i> , 2014, 6, 27.	8.2	41
21	The effects of different endocrine disruptors defining compound-specific alterations of gene expression profiles in the developing testis. <i>Reproductive Toxicology</i> , 2012, 33, 106-115.	2.9	39
22	Monitoring vascular normalization induced by antiangiogenic treatment with 18F- ¹⁸ F-fluoromisonidazole- ¹⁸ F-PET. <i>Molecular Oncology</i> , 2016, 10, 704-718.	4.6	36
23	Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1751-1760.	4.1	31
24	Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. <i>Oncotarget</i> , 2015, 6, 8539-8551.	1.8	31
25	Gene-expression profiling in pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 591-601.	3.1	30
26	A multifunctional drug nanocarrier for efficient anticancer therapy. <i>Journal of Controlled Release</i> , 2019, 294, 154-164.	9.9	29
27	Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. <i>PLoS ONE</i> , 2015, 10, e0142631.	2.5	28
28	New scaffolds for the design of selective estrogen receptor modulators. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3486.	2.8	24
29	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	2.6	24
30	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. <i>Proteomics</i> , 2012, 12, 1319-1327.	2.2	22
31	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its <i>in vivo</i> synergism with gemcitabine. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1461-1471.	2.4	21
32	A Tricin Derivative from <i>Deschampsia antarctica</i> Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 966-976.	4.1	21
33	Gene silencing by RNAi in mouse Sertoli cells. <i>Reproductive Biology and Endocrinology</i> , 2008, 6, 29.	3.3	18
34	Regulation of flotillin-1 in the establishment of NIH-3T3 cell-cell interactions ¹ . <i>FEBS Letters</i> , 2003, 555, 223-228.	2.8	15
35	Expression of stress inducible protein 1 (Stip1) in the mouse testis. <i>Molecular Reproduction and Development</i> , 2006, 73, 1361-1366.	2.0	15
36	Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00067.	2.4	14

#	ARTICLE	IF	CITATIONS
37	Phosphoprotein enriched in astrocytes-15 is expressed in mouse testis and protects spermatocytes from apoptosis. <i>Reproduction</i> , 2007, 133, 743-751.	2.6	13
38	MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-13.	0.8	13
39	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. <i>Public Health Genomics</i> , 2017, 20, 81-91.	1.0	10
40	Changes in Vinexin Expression Patterns in the Mouse Testis Induced by Developmental Exposure to 17Beta-Estradiol. <i>Biology of Reproduction</i> , 2007, 77, 605-613.	2.7	9
41	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , 2021, 13, 2334.	3.7	9
42	Ran GTPase expression during early development of the mouse embryo. <i>Mechanisms of Development</i> , 2002, 113, 103-106.	1.7	8
43	Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. <i>Nature Medicine</i> , 2014, 20, 1230-1231.	30.7	8
44	Reply: â€”Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancerâ€™. <i>British Journal of Cancer</i> , 2014, 111, 1677-1678.	6.4	2
45	Cell-free circulating tumour DNA as a tool for monitoring response to anti-EGFR therapies of mCCR.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23059-e23059.	1.6	0